0001819790-21-000059.txt : 20211203
0001819790-21-000059.hdr.sgml : 20211203
20211203185658
ACCESSION NUMBER: 0001819790-21-000059
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211201
FILED AS OF DATE: 20211203
DATE AS OF CHANGE: 20211203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ackermann Michael
CENTRAL INDEX KEY: 0001791249
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 211471530
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wf-form4_163857580594057.xml
FORM 4
X0306
4
2021-12-01
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001791249
Ackermann Michael
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
1
0
0
0
Common Stock
2021-12-01
4
S
0
2442
23.85
D
1207407
D
Common Stock
2021-12-01
4
S
0
2054
24.68
D
1205353
D
Common Stock
2021-12-01
4
S
0
809
25.87
D
1204544
D
Common Stock
2021-12-01
4
S
0
528
26.65
D
1204016
D
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $23.24 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.28 to $25.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.51 to $26.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.53 to $27.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Leonard M. Greenstein, Attorney-in-Fact
2021-12-03